



LabStyle Innovations Corp.

CORPORATE HEADQUARTERS

9 Halamish Street, 1st Floor
Caesarea Industrial Park, 38900
Israel
www.mydario.com

Industry: Software/Medical Device
Year End: December 31

STOCK SUMMARY

Symbol: DRIO

MANAGEMENT TEAM

Erez Raphael
Acting Chairman/CEO & President

Gadi Levin
CFO

Professor Itamar Raz MD
Head of SAB

Shosh Friedman
VP Clinical & Regulatory Affairs

Eran Kurman
VP, Global Commercial Strategy

Dror Bacher
VP, Research and Development

David Edelman
Director Product Strategy

INVESTOR RELATIONS/PRESS INQUIRIES

Brenda Zeitlin
1 800 896 9062
brenda@mydario.com

LabStyle Innovations Corp. (OTCQB: DRIO) believes that a platform for connecting medical devices to ongoing data collection, analysis and support tools will transform the quality of diabetes care.

LabStyle's flagship product, Dario™, empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.

Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter.

LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and guided by a world class board of directors and scientific advisory board.

COMPANY MILESTONES

- Founded in 2011 and commenced trading on OTCQB Market. (April 2013)
- Granted a CE Mark for the full Dario diabetes management system which allows for marketing in Europe. (September 2013)
- Signed exclusive distribution agreements in United Kingdom, Australia, New Zealand, Sweden, Italy, Netherlands and Canada. (During 2013 and 2014)
- Launch of the Dario™ iOS mobile app in the UK, New Zealand and Italy.
- Filed 510(k) FDA clearance for marketing the Dario™ device and iOS app. (December 2013)
- Closed a \$4.19 million placement financing. (February 2014)
- Launch of the Dario™ glucose monitoring device in the United Kingdom, New Zealand and Italy (Q2 2014)
- Received reimbursement coverage in the UK and Italy (Q2 & Q3 2014)
- Closed a \$4.24 million private placement financing (September 2014)
- Expanding to the rest of the world (throughout 2014 and 2015)
- Launch of the Dario™ platform monitoring device in the United States (throughout 2015)
- Launch of the next Generation Dario™ blood glucose monitoring device (2015)

MARKET

- Diabetes is a fast growing epidemic with more than 382 million people living with diabetes worldwide. This number is expected to grow to 592 million by 2035.¹ The total cost of diabetes in the United States was US\$245 billion in 2012.²
- The global diagnosis and monitoring devices market is expected to reach US\$26.0 billion by 2018, growing at a CAGR of 7.8% from 2011 to 2018;³ in addition, the total diabetes management market was US\$50.8 billion in 2011 and is estimated to reach US\$98.4 billion by 2018.³
- The global self-monitoring blood glucose market was US\$9.7 billion in 2011 and expected to reach US\$27.4 billion in 2022.⁴

MISSION

- Deliver the best diabetes self-monitoring platform.
 - Stylish, all-in-one smartphone-powered blood glucose monitoring platform (stylish, all-in-one device, app and cloud).
 - Test strips provide a significant high margin, recurring revenue stream. Pricing plans are competitive with high-end test strips in the market.
 - Third-party distribution augmented by direct-to-consumer sales in certain jurisdictions, supported by an efficient, online-driven marketing approach.
- Enable health providers to better identify and manage population risk.
 - Prioritize patient interventions based on real-time health data.
 - Provide evidence-based clinical decision support.
- Monetize data by sharing personalized product and service recommendations, supporting clinical trial recruitment, and online advertising.
- Support health providers with evidence-based health improvement and cost-reduction systems.

